Schizophrenia
Second line
Second-line for schizophrenia per 2020. Starting dose 20 mg twice daily, titrated to 40–80 mg twice daily. Advantage: minimal metabolic impact; preferred in patients with metabolic syndrome, obesity, diabetes. Huhn 2019 network meta-analysis showed lower efficacy than olanzapine and but better metabolic tolerability.